Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Watson Pharma Defends Ascent Buyout; Bigger Scale Will Offset Price Cuts In Australia

This article was originally published in PharmAsia News

You may also be interested in...



Watson Pulls Prochieve From Guidance, But Pushes For Approval

Despite a disappointing advisory committee review for its progesterone gel for preterm birth, Watson said it will continue to push for approval. The company also bolsters its Australian generics business with the acquisition of Ascent.

Emerging Markets Round Up From JP Morgan Healthcare Conference (Part 2 of 2)

[Editor's note: This is part two of a story carrying highlights on emerging markets from the annual JP Morgan Healthcare Conference in San Francisco last week.

Watson Takes Stake In Brazil's Moksha8

The Sao Paolo-based company will market about a dozen of Watson's generics in Mexico and Brazil, with potential for more.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC079400

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel